Table 2: Key eligibility criteria for reimbursement of simeprevir with peginterferon plus ribavirin for treatment of hepatitis C virus infection, by jurisdiction.

Jurisdiction	Restriction
	Minimum fibrosis stage required	Substance use	HIV coinfection	Prescriber	Decompensated cirrhosis
Province/territory
British Columbia	F2	None listed	None listed	General practitioner	None listed
Alberta	F2	None listed	None listed	None listed	Ineligible
Saskatchewan	F2	None listed	None listed	General practitioner	None listed
Manitoba	F2	None listed	Eligible	Specialist	Ineligible
Ontario	F2	None listed	Eligible	General practitioner	Ineligible
Quebec	None listed*	None listed	Ineligible†	None listed	None listed
New Brunswick	F2	None listed	None listed	None listed	Ineligible
Nova Scotia	F2	None listed	None listed	Specialist‡	Ineligible
Prince Edward Island	NA	NA	NA	NA	NA
Newfoundland and Labrador	F2	None listed	None listed	None listed	Ineligible
Yukon	F2	None listed	None listed	Specialist	Ineligible
Northwest Territories	F2	None listed	None listed	Specialist‡	None listed
Nunavut	F2	None listed	None listed	Specialist‡	None listed
Federal
Non-Insured Health Benefits Program	F2	None listed	None listed	Specialist‡	None listed
Correctional Service Canada	F2§	None listed¶	None listed	None listed	None listed

Note: NA = not available.

*However, coauthors indicated that in practice there were no fibrosis stage restrictions.

†However, exceptions could be granted via the "patient d'exception" (exception patient) measure.

‡None listed in criteria; however, a specialist prescription was required for peginterferon-based treatments.

§Treatment prioritized to patients with stage F3 or F4 fibrosis; treatment for those with stage F0, F1 or F2 fibrosis was reviewed on a case-by-case basis.

¶Directly observed therapy required.